Entospletinib

Entospletinib
Clinical data
Other names	GS-9973
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name 6-(1H-Indazol-6-yl)-N-(4-morpholin-4-ylphenyl)imidazo[1,2-a]pyrazin-8-amine;
CAS Number	1229208-44-9;
PubChem CID	59473233;
DrugBank	12121;
UNII	6I3O3W6O3B;
KEGG	D11209;
CompTox Dashboard (EPA)	DTXSID001317670 ;
Chemical and physical data
Formula	C23H21N7O
Molar mass	411.469 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES c1cn2cc(-c3ccc4cn[nH]c4c3)nc(Nc3ccc(N4CCOCC4)cc3)c2n1;
	InChI InChI=1S/C23H21N7O/c1-2-17-14-25-28-20(17)13-16(1)21-15-30-8-7-24-23(30)22(27-21)26-18-3-5-19(6-4-18)29-9-11-31-12-10-29/h1-8,13-15H,9-12H2,(H,25,28)(H,26,27); Key:XSMSNFMDVXXHGJ-UHFFFAOYSA-N;

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

Entospletinib is an experimental drug for the treatment of various types of cancer under development by Gilead Sciences. It is an inhibitor of spleen tyrosine kinase (Syk).^[1] It has entered clinical trials for acute myeloid leukaemia (AML), chronic lymphocytic leukemia (CLL),^[2] diffuse large B cell lymphoma (DLBCL), graft-versus-host disease (GvHD), hematological malignancies, mantle cell lymphoma (MCL), and non-Hodgkin lymphoma (NHL).^[3]

References

^ "Definition of entospletinib". NCI Cancer Dictionary. National Cancer Institute.
^ Sharman J, Di Paolo J (June 2016). "Targeting B-cell receptor signaling kinases in chronic lymphocytic leukemia: the promise of entospletinib". Therapeutic Advances in Hematology. 7 (3): 157–70. doi:10.1177/2040620716636542. PMC 4872176. PMID 27247756.
^ "Entospletinib - Gilead Sciences". Adis Insight.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

[1] "Definition of entospletinib". NCI Cancer Dictionary. National Cancer Institute.

[pmid27247756-2] Sharman J, Di Paolo J (June 2016). "Targeting B-cell receptor signaling kinases in chronic lymphocytic leukemia: the promise of entospletinib". Therapeutic Advances in Hematology. 7 (3): 157–70. doi:10.1177/2040620716636542. PMC 4872176. PMID 27247756.

[3] "Entospletinib - Gilead Sciences". Adis Insight.

[1]

[2]

[3]